Expanding SCINTIX Biology-Guided Radiotherapy Beyond Lung and Bone: A Planning Feasibility and Dosimetric Study on the RefleXion X1 System.

Haozhao Zhang^1,2, Grant Gibbard³, Chenyang Shen^1,2, Thomas I Banks^1,2, Hao Peng^1,2, Angela Da Silva³, Gopinath Kuduvalli³, Todd A Aguilera¹, Tu Dan¹, Shahed N Badiyan¹, Kenneth Westover¹, David J Sher¹, Aurelie Garant¹, Raquibul Hannan¹, Steve B Jiang^1,2, Orhan K Oz⁴, Robert D Timmerman¹, Bin Cai^1,2

¹Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, USA.

²Medical Artificial Intelligence and Automation Laboratory, The University of Texas Southwestern Medical Center, Dallas, TX, USA.

³RefleXion Medical, Hayward, CA, USA.

⁴Department of Radiology, The University of Texas Southwestern Medical Center, Dallas, TX, USA.

PubMed PMC DOI PDF

Abstract

IntroductionSCINTIX® therapy, a form of biology-guided radiotherapy using real-time positron emission tomography (PET) imaging on the RefleXion® X1 platform, recently received FDA clearance for FDG-guided treatment of lung and bone tumors. This study evaluates the feasibility and dosimetric quality of Biology-Guided Radiotherapy (BgRT) plans for FDG-avid lesions in anatomical sites beyond current…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.